Stephen Hemsley hasn’t been CEO at UnitedHealth Group in nearly a decade yet he’s never really left. Hemsley, 72, has remained chairman and a major shareholder in the health care behemoth — and now is back in the CEO

UnitedHealth Group stock has plummeted since my last Buy rating and is ~55% off highs, but its lower valuation now offers a significant margin of

Wall Street dipped on Thursday as elation from the U.S.-China tariff truce faded for major indexes, while UnitedHealth's stock took a pummeling after a report of a DOJ fraud inquiry into the insurer.

Shares of UnitedHealth Group tumbled more than 15% in morning trade on Thursday after a report said that the Justice Department is investigating the health insurer for potential fraud.

UnitedHealth Group's stock has plunged nearly 50% due to the CEO resignation, withdrawal of guidance, and ongoing legal issues, creating a potential buying opportunity. The stock is deeply oversold with an RSI of 15, trading below both the 200-day and 50-day moving averages, indicating capitulation.

UnitedHealth Group's stock has collapsed nearly 50% in 2025 after a leadership shake-up, surging medical costs, and a DOJ criminal probe into Medicare fraud.

Hemsley, 72, had led the company for more than a decade until 2017 and is re-taking the reins following a series of setbacks.

UnitedHealth faces valuation reset amid CEO change, regulatory probes, and cost overruns. Click here for a full analysis of UNH stock.